Insiders · Profile

ZANTE GREG

Chief Financial Officer at Viking Therapeutics. Filing since 30 Mar 2023. CIK 0001264949

Company

Date

Role

Action

Shares

Amount

Of holding

VKTX Viking Therapeutics, Inc.

29 Jul 2026

Chief Financial Officer

Sold at will

21,217

$710.14K

9.1%

VKTX Viking Therapeutics, Inc.

5 Jan 2026

Chief Financial Officer

Sold at will

57,661

$1.90M

23.3%

VKTX Viking Therapeutics, Inc.

28 Oct 2025

Chief Financial Officer

Sold at will

6,185

$216.48K

3.4%

VKTX Viking Therapeutics, Inc.

3 Jul 2025

Chief Financial Officer

Sold at will

4,266

$118.43K

2.5%

VKTX Viking Therapeutics, Inc.

6 Jan 2025

Chief Financial Officer

Sold at will

50,309

$2.15M

23.3%

VKTX Viking Therapeutics, Inc.

28 Oct 2024

Chief Financial Officer

Sold on a plan

131,687

$10.09M

46.9%

VKTX Viking Therapeutics, Inc.

30 Jul 2024

Chief Financial Officer

Sold at will

16,136

$922.21K

7.9%

VKTX Viking Therapeutics, Inc.

3 May 2024

Chief Financial Officer

Sold on a plan

66,756

$4.99M

27.6%

VKTX Viking Therapeutics, Inc.

4 Jan 2024

Chief Financial Officer

Sold at will

15,000

$268.50K

7.7%

VKTX Viking Therapeutics, Inc.

17 Apr 2023

Chief Financial Officer

Sold at will

7,500

$150.00K

4.8%

VKTX Viking Therapeutics, Inc.

12 Apr 2023

Chief Financial Officer

Sold at will

41,544

$747.79K

21.8%

VKTX Viking Therapeutics, Inc.

11 Apr 2023

Chief Financial Officer

Sold at will

56,295

$1.01M

27.4%

VKTX Viking Therapeutics, Inc.

3 Apr 2023

Chief Financial Officer

Sold at will

30,911

$556.40K

17.3%

VKTX Viking Therapeutics, Inc.

30 Mar 2023

Chief Financial Officer

Sold at will

131,029

$2.23M

47.0%

14 decisions on file.